Chester County News and Community Website
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its financial results for the fourth quarter and fiscal year 2024, alongside significant corporate updates. The biotechnology company reaffirmed its commitment …
Arbutus Biopharma Reports 2024 Financial Results and Strategic Updates Read More
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced significant changes to its leadership team, naming Lindsay Androski, J.D., M.B.A., as Chief Executive Officer. Ms. Androski succeeds Michael J. McElhaugh, …
Arbutus Biopharma Appoints Lindsay Androski as CEO Amid Leadership Restructuring Read More WARMINSTER, PA — Arbutus Biopharma Corporation (NASDAQ: ABUS) has unveiled its strategic objectives for 2025 alongside an encouraging financial update, emphasizing progress in its efforts to develop a functional cure for …
Arbutus Biopharma Sets Sights on Advancing HBV Cure in 2025 Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced promising new data from its IM-PROVE I Phase 2a clinical trial, suggesting significant advancements in treatment for chronic hepatitis B …
Arbutus Biopharma’s Clinical Trial Shows Promise for Hepatitis B Treatment Read More WARMINSTER, PA and OXFORD, United Kingdom — Arbutus Biopharma Corporation and Barinthus Biotherapeutics recently unveiled encouraging preliminary results from their Phase 2a IM-PROVE II clinical trial at the American Association …
Promising New Data from Hepatitis B Trial by Arbutus and Barinthus Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has released its third-quarter 2024 financial results, showcasing significant progress in its clinical trials and a stable financial position. The company is …
Arbutus Biopharma Advances Clinical Trials and Strengthens Financial Position in Q3 2024 Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its second quarter 2024 financial results and provided an update on its corporate strategy.
Arbutus Biopharma Reports Promising Data and Restructuring Plans in Q2 2024 Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its plans to release its second quarter 2024 financial results and provide a corporate update on Thursday, August 1, 2024.
Arbutus Biopharma to Reveal Q2 Financials and Corporate Updates Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has released new data from their Phase 2a clinical trial, IM-PROVE I, revealing that imdusiran, their RNAi therapeutic, in combination with a …
Advancing Towards a Functional Cure: Promising Results in Hepatitis B Treatment Read More WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the upcoming retirement of its co-founder and Chief Scientific Officer, Dr. Michael Sofia, effective December 31, 2024. Dr. Sofia, a recipient …
Arbutus Biopharma Co-Founder Dr. Michael Sofia to Retire After a Storied Career in Antiviral Drug Discovery Read More